ACADIA PHARMACEUTICALS INC

Acadia Pharmaceuticals insider insight: Mark C. Schneyer’s net‑long buy/sell pattern signals confidence and potential upside for Parkinson’s and schizophrenia pipeline.

Insider sale at Acadia Pharmaceuticals shows routine portfolio rebalancing amid rising option activity and pending EU approval, giving investors a clear view of executive trading trends.

Investor alert: Baker Bros. Advisors ups Acadia stake, adding RSUs/​options that signal confidence in its CNS pipeline—watch for future dilution and upside potential.

Insider selling of ACADIA shares continues quietly—small block trades by James Kihara show no immediate impact on price, so focus remains on the company’s clinical pipeline.

Insider moves at Acadia Pharmaceuticals show executives buying and selling stock to manage tax and liquidity, yet still hold long‑term confidence in the company’s CNS pipeline.

ACADIA insider activity: CEO Owen Adams Catherine buys 23k shares at zero cost while selling RSUs, signaling confidence and strategic liquidity management.

Acadia CFO’s insider buys signal confidence in its Parkinson’s and schizophrenia pipeline – a subtle RSU strategy hinting at future upside.

ACADIA insider buying: EVP Jennifer Rhodes adds 12,944 free RSU shares, boosting confidence in the CNS pipeline and near‑term prospects.